
Homies Unidos helps Denver youth find a road to peace and mental health
For a decade now, an organization called "Homies Unidos" has challenged youth in Denver to "believe in the possibility of a world without violence."
"Homies" aims to address the root causes of gang violence by promoting a positive sense of community and creative expression, helping youth from across metro Denver build resilience.
Greg Rodriguez is studying audio engineering at the Community College of Denver. He's recently taken a leadership role working with an environmental group.
"We go around the parks, we clean the trash, we go around the creekway, we make sure they're clean," said Rodriguez.
Greg Rodriguez
Greg attributes his success with charting a healthy path to Homies Unidos, the group that helps youth at risk of joining gangs to make sense of a complex and often dangerous world.
Homies Unidos Denver is led by Executive Director Gerardo Lopez, who himself - years ago - found a way out.
"These kids do experience trauma, whether it's shootings, whether it's violence," said Lopez. "So we try to tackle those issues and create a safe environment for them to feel comfortable."
There's a strong focus on mental health, as youth learn how to understand their own emotions and each other.
"Those walls start to come down, and they start to look at each other as normalizing each other, looking at each other as human beings," Lopez said, "So they think twice about hurting each other and causing harm to someone else."
Homies Unidos Denver
"When youth are able to talk about the importance of mental health, the importance of healing, the importance of addressing trauma, they can also help their family members heal as well," said Caring for Denver Foundation Executive Director Lorez Meinhold. Caring for Denver helps fund Homies' mental health initiatives.
In the Homies' offices and in the community, young people use tools like virtual reality to explore.
Greg Rodriguez uses the studio to create podcasts and other content peers can relate to. He says he has learned to think differently.
"I used to view situations as there's one way in and one way out. There's no other options. Like there's more than one option. That explore your options and see which one's best for you," said Rodriguez.
And he's closer to his family, "I can actually like, 'Oh mama got this on my mind. Or like, all the stuff about this', we can have, like a deep conversation about it."
CBS
Learning concrete skills in how to manage adversity and build character, Homies Unidos' programming reaches a couple hundred youth across more than a dozen schools every year.
Thursday, May 15, CBS Colorado will recognize Mental Health Action Day by saluting the efforts of people in our state working to promote emotional health for themselves and their communities.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 days ago
- Yahoo
NM attorney general and two manufacturers cap diabetes drug costs in settlements
A pharmacy manager retrieves a bottle of antibiotics. (Photo by) Under settlement agreements reached earlier this year and announced by New Mexico Attorney General Raúl Torrez on Wednesday, two insulin manufacturers have committed to make the diabetes treatment cheaper for New Mexicans. 'These are huge wins for New Mexicans who have struggled with the outrageous cost of insulin,' Torrez said in a statement. 'These agreements will help people stop rationing medication, avoid financial hardship, and focus on staying healthy. We are holding drug manufacturers accountable and making access to life-saving treatment more equitable.' New Mexico Department of Justice spokesperson Lauren Rodriguez told Source NM that the agreements provide insured patients who might have a high deductible or copay the option to pay cash instead of using their insurance, and to pay no more than $35 for a monthly supply of insulin, Rodriguez said. The New Mexico state law enacted in 2020 that caps insulin costs at $25 remains in full force and is not preempted or replaced by the new settlements, Rodriguez said. Instead, the agreements are 'additive protections mainly aimed at helping cash-paying and uninsured patients, while deferring to state law when it offers better pricing,' she said. As many as 207,600 adults in New Mexico, or approximately 11% of the state's adult population, have diabetes, according to the American Diabetes Association. Without the caps, patients in other states could pay $150 per month or more, especially if they require multiple variations of the drug, Stateline reports. More states are doing what they can to cap insulin costs High out-of-pocket costs have historically forced many patients to choose between buying insulin and meeting other basic needs, NMDOJ said in a news release. The settlements result from the agency's independent investigations into insulin pricing practices, NMDOJ said. The state's agreement with Sanofi-Aventis U.S. LLC, signed on April 18, requires the company to maintain its Insulins ValYou Savings Program, which allows patients who pay out-of-pocket to receive a month's supply for $35. The Sanofi settlement also requires it to maintain its Patient Connection Program, which allows uninsured patients who aren't eligible for Medicaid and whose annual household income is at or below 400% of the federal poverty line to receive insulin for free. Under the settlement, Sanofi must also provide patients live phone and translation support in Spanish, Hmong, Somali and Mandarin Chinese; and participating pharmacies will receive training to help patients enroll in affordability programs. The settlement with Novo Nordisk Inc., signed on May 19, requires the company to maintain its MyInsulinRX Program, which offers diabetes patients the option to pay $35 or less for a monthly prescription. Under the agreement, Novo Nordisk must also continue its Patient Assistance Program, which offers insulin for free. The settlement also requires Novo Nordisk to notify pharmacies about available discounts at the point of sale, help patients enroll on the spot and offer live phone and website chat support in Spanish. Reporter Danielle Prokop contributed reporting to this story. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Yahoo
7 days ago
- Yahoo
DVA Q1 Earnings Call: Cyber Incident, Volume Decline, and Policy Updates Shape Outlook
Dialysis provider DaVita Inc. (NYSE:DVA) fell short of the market's revenue expectations in Q1 CY2025 as sales rose 5% year on year to $3.22 billion. Its non-GAAP EPS of $2 per share was 1% below analysts' consensus estimates. Is now the time to buy DVA? Find out in our full research report (it's free). Revenue: $3.22 billion (5% year-on-year growth) Adjusted EPS: $2 vs analyst expectations of $2.02 (1% miss) Management reiterated its full-year Adjusted EPS guidance of $10.75 at the midpoint Operating Margin: 13.6%, down from 15.8% in the same quarter last year Sales Volumes fell 1.6% year on year (0.5% in the same quarter last year) Market Capitalization: $10.27 billion DaVita's first quarter results were influenced by several operational and external factors, as discussed by management. CEO Javier Rodriguez highlighted the impact of an abnormally severe flu season, which contributed to higher missed treatment rates and increased patient mortality, resulting in lower treatment volumes. Additionally, Rodriguez noted that phosphate binders, now reimbursed under the new CMS policy, provided a meaningful tailwind to revenue per treatment. CFO Joel Ackerman pointed out that the company's international segment performed well, building on previous acquisitions, and that disciplined expense management contributed positively to operating income. Management also addressed a recently disclosed cybersecurity incident, emphasizing that patient care was maintained without interruption, though some operational costs will be recognized in the following quarter. Looking forward, DaVita's outlook for the rest of the year centers on navigating ongoing headwinds and capitalizing on regulatory shifts. Management reiterated its full-year adjusted earnings per share guidance, citing confidence in the business's underlying strength despite anticipated pressures from the recent cyberattack and lower treatment volumes. Rodriguez explained, 'The underlying strength of our business performance in the first quarter and the increase in our forecast for profitability of orals in the bundle give us confidence in our full-year guidance.' The company is also closely monitoring potential policy changes, including the expiration of enhanced premium tax credits and their cumulative effect on operating income, as well as the evolving landscape for phosphate binder reimbursement. Management acknowledged that while some risks remain, including regulatory and volume-related uncertainties, initial trends in new patient admissions and drug mix have been encouraging. Management attributed quarterly results to lower-than-expected treatment volumes from elevated flu activity, a favorable mix of phosphate binders, and strong international operations. The company also highlighted the operational impact of a recent cybersecurity incident and evolving reimbursement policies. Flu and treatment volume: Management reported that the severe flu season led to higher missed treatment rates and increased patient mortality, resulting in a notable decline in overall treatment volumes compared to forecasts. This decrease was further exacerbated by winter storms early in the quarter. Phosphate binder reimbursement: The transition of phosphate binders into the CMS dialysis benefit contributed positively to revenue per treatment. Management described an uptick in prescriptions for iron-based binders, which are more effective for certain patients, resulting in higher-than-expected profitability from this drug class. International segment performance: The company's international business showed improved operating income, supported by the integration of recent acquisitions, particularly in Latin America. Management expressed optimism about the ongoing contribution from these markets. Cybersecurity incident response: DaVita's operations faced disruption after a cyberattack in April, but management emphasized that dialysis care continued without interruption. Most major systems were restored quickly, and financial impacts are expected to be largely one-time costs recognized in the next quarter. Capital allocation approach: The company accelerated share repurchases in the first part of the year, consistent with its ongoing strategy to invest in growth opportunities and return capital to shareholders. Management indicated that repurchase activity will slow for the balance of the year, maintaining its established allocation priorities. Management's outlook for the remainder of the year is shaped by expectations for treatment volume recovery, evolving drug reimbursement, and potential policy changes affecting patient mix and profitability. Volume recovery uncertainty: Management anticipates that treatment volumes will remain below initial projections for the year, primarily due to the lingering effects of the severe flu season and temporary admissions disruptions from the cyberattack. The company expects gradual volume improvement but does not provide a clear timeline for a return to 2% growth. Phosphate binders' impact: The ongoing integration of phosphate binders into the Medicare bundle is expected to support revenue per treatment, especially given the strong initial uptake of iron-based binders. Management believes this could provide incremental operating income at the upper end of its previously guided range, though variability in drug mix remains a risk. Policy and reimbursement risks: The company remains vigilant about potential policy changes, such as the expiration of enhanced premium tax credits, which could cumulatively impact operating income over several years. Management is also monitoring evolving Medicaid and tariff policies, though it currently does not expect these to materially affect results. In the coming quarters, the StockStory team will be tracking (1) the pace of recovery in treatment volumes as the effects of the flu season and cyber incident subside, (2) continued progress on integrating phosphate binders into the reimbursement model and their impact on operating income, and (3) updates on international expansion, particularly in Latin America. Additionally, we will monitor any changes in healthcare policy or reimbursement that could influence patient mix and profitability. DaVita currently trades at a forward P/E ratio of 11.8×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Yahoo
Another Top MN Twins Prospect Hits the IL
The Minnesota Twins have trended back towards a clean bill of health at the major league level. Royce Lewis has been back for a while now, and both Byron Buxton and Carlos Correa returned from their collision. Matt Wallner became the latest to rejoin Rocco Baldelli's 31-27 squad over the weekend. Unfortunately the top prospect health has not been as great on the farm. Walker Jenkins has played just two games this season after dealing with an ankle injury that stems from Spring Training. Emmanuel Rodriguez also suffered an ankle injury around the same time but has been available. Advertisement That is until now. Rodriguez has had a relatively consistent career of injuries, and his latest lands him on the St. Paul Saints injured list. Emmanuel Rodriguez injured at Triple-A for Minnesota Twins If there are three things synonymous with Emmanuel Rodriguez they are patience, power, and injuries. The Minnesota Twins star prospect has constantly been tied to all three during his professional career. A new injury, this time his right hip, lands him on the Triple-A injured list. Rodriguez last played on May 30 for St. Paul. He was lifted for Jeferson Morales and then missed each of the Saints last two games. Minnesota responded by placing him on the injured list with a right hip issue. Advertisement Last season Rodriguez played in just 47 games after dealing with a thumb injury that ultimately required season-ending surgery. He got 99 games in with Cedar Rapids during 2023, but it's the only season of his five-year career in which he has played more than 47 games. This year, his first full season at Triple-A, Rodriguez has performed to his offensive track record. He owns a .232/.400/.392 slash line. The outfielder has posted six doubles, a triple, and four home runs with a 56/32 K/BB ratio. Rodriguez is a capable centerfielder that is more likely destined for a corner spot. His patience at the plate can be to his detriment, and is a reason the average sags. He does have legitimate plus-power and is considered a consensus top 25 prospect across baseball. Advertisement Amidst the roster shuffling for St. Paul, they do get Payton Eeles back. He is an independent baseball success story that has climbed the Twins minor league ranks. The 25-year-old made it from Single-A to Triple-A last season and owned a .299/.419/.500 line with St. Paul across 64 games. It wouldn't be a shock to see the utility infielder debut with Minnesota this season. How long will the Twins miss E-Rod this time? Each year an injury seems to befall Rodriguez and the Minnesota Twins prospect misses a sizable chunk of time. The severity of this hip injury has not yet been reported, but the timing isn't great. Rodriguez is on the 40-man and would be a candidate to make his big league debut. ESPN Insider Kiley McDaniel recently noted this exact scenario for Rodriguez. 'Rodriguez gets hurt a lot but is at Triple-A doing his usual thing: low average, crazy-high walk rate, power and solid center-field defense.' Kiley McDaniel – ESPN McDaniel called Rodriguez the Twins 'next to debut' but this certainly throws water on that. Carson McCusker got a promotion only after a rash of injuries. DaShawn Keirsey Jr. was optioned after Matt Wallner returned, and his .109/.136/.156 line won't earn him a return all too soon. Advertisement Theoretically Rodriguez could have been next in line if Minnesota needed a regular outfielder. The 22 year old's latest injury puts a wrench in the plan though. The hope should be that this injury doesn't cost him significant time, but that's never been a reality for the Dominican Republic native. Related Headlines